Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway
Parkinson’s disease (PD) is one of the major neurodegenerative diseases (ND) which presents a progressive neurodegeneration characterized by loss of dopamine in the substantia nigra pars compacta. It is well known that oxidative stress, inflammation and glutamatergic pathway play key roles in the de...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/2/230 |
| _version_ | 1797407562682859520 |
|---|---|
| author | Alexandre Vallée Jean-Noël Vallée Yves Lecarpentier |
| author_facet | Alexandre Vallée Jean-Noël Vallée Yves Lecarpentier |
| author_sort | Alexandre Vallée |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is one of the major neurodegenerative diseases (ND) which presents a progressive neurodegeneration characterized by loss of dopamine in the substantia nigra pars compacta. It is well known that oxidative stress, inflammation and glutamatergic pathway play key roles in the development of PD. However, therapies remain uncertain and research for new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on PD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3beta, the main inhibitor of the WNT/β-catenin pathway. The stimulation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in PD. |
| first_indexed | 2024-03-09T03:43:22Z |
| format | Article |
| id | doaj.art-53f1e92e6341403e917699933e34079c |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T03:43:22Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-53f1e92e6341403e917699933e34079c2023-12-03T14:36:44ZengMDPI AGCells2073-44092021-01-0110223010.3390/cells10020230Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic PathwayAlexandre Vallée0Jean-Noël Vallée1Yves Lecarpentier2Department of Clinical Research and Innovation (DRCI), Hôpital Foch, 92150 Suresnes, FranceCentre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules Verne (UPJV), 80054 Amiens, FranceCentre de Recherche Clinique, Grand Hôpital de l’Est Francilien (GHEF), 6-8 rue Saint-Fiacre, 77100 Meaux, FranceParkinson’s disease (PD) is one of the major neurodegenerative diseases (ND) which presents a progressive neurodegeneration characterized by loss of dopamine in the substantia nigra pars compacta. It is well known that oxidative stress, inflammation and glutamatergic pathway play key roles in the development of PD. However, therapies remain uncertain and research for new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on PD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3beta, the main inhibitor of the WNT/β-catenin pathway. The stimulation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in PD.https://www.mdpi.com/2073-4409/10/2/230WNT/beta-catenin pathwaylithiumParkinsoninflammationoxidative stressglutamatergic pathway |
| spellingShingle | Alexandre Vallée Jean-Noël Vallée Yves Lecarpentier Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway Cells WNT/beta-catenin pathway lithium Parkinson inflammation oxidative stress glutamatergic pathway |
| title | Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway |
| title_full | Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway |
| title_fullStr | Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway |
| title_full_unstemmed | Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway |
| title_short | Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway |
| title_sort | parkinson s disease potential actions of lithium by targeting the wnt β catenin pathway oxidative stress inflammation and glutamatergic pathway |
| topic | WNT/beta-catenin pathway lithium Parkinson inflammation oxidative stress glutamatergic pathway |
| url | https://www.mdpi.com/2073-4409/10/2/230 |
| work_keys_str_mv | AT alexandrevallee parkinsonsdiseasepotentialactionsoflithiumbytargetingthewntbcateninpathwayoxidativestressinflammationandglutamatergicpathway AT jeannoelvallee parkinsonsdiseasepotentialactionsoflithiumbytargetingthewntbcateninpathwayoxidativestressinflammationandglutamatergicpathway AT yveslecarpentier parkinsonsdiseasepotentialactionsoflithiumbytargetingthewntbcateninpathwayoxidativestressinflammationandglutamatergicpathway |